共 374 条
[1]
Lampertico P(2017)EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection J Hepatol 67 370-398
[2]
Agarwal K(2017)The burden of primary liver Cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study 2015 JAMA Oncol 3 1683-1691
[3]
Berg T(2016)Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Hepatol Int 10 1-98
[4]
Buti M(2018)Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Hepatology 67 1560-1599
[5]
Janssen HLA(2015)Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy J Hepatol 62 956-967
[6]
Papatheodoridis G(2010)Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 348-356
[7]
Zoulim F(2013)Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B Aliment Pharmacol Ther 38 98-106
[8]
Tacke F(2019)The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis BMC Cancer 19 511-20
[9]
Akinyemiju T(2017)Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study J Viral Hepat 24 12-476
[10]
Abera S(2020)Tenofovir treatment has lower risk of hepatocellular carcinoma than Entecavir treatment in patients with chronic hepatitis B: a systematic review and Meta-analysis Liver Cancer 9 468-914